220 related articles for article (PubMed ID: 19188184)
1. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer.
Speetjens FM; Kuppen PJ; Welters MJ; Essahsah F; Voet van den Brink AM; Lantrua MG; Valentijn AR; Oostendorp J; Fathers LM; Nijman HW; Drijfhout JW; van de Velde CJ; Melief CJ; van der Burg SH
Clin Cancer Res; 2009 Feb; 15(3):1086-95. PubMed ID: 19188184
[TBL] [Abstract][Full Text] [Related]
2. Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial.
Zeestraten EC; Speetjens FM; Welters MJ; Saadatmand S; Stynenbosch LF; Jongen R; Kapiteijn E; Gelderblom H; Nijman HW; Valentijn AR; Oostendorp J; Fathers LM; Drijfhout JW; van de Velde CJ; Kuppen PJ; van der Burg SH; Melief CJ
Int J Cancer; 2013 Apr; 132(7):1581-91. PubMed ID: 22948952
[TBL] [Abstract][Full Text] [Related]
3. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.
Leffers N; Lambeck AJ; Gooden MJ; Hoogeboom BN; Wolf R; Hamming IE; Hepkema BG; Willemse PH; Molmans BH; Hollema H; Drijfhout JW; Sluiter WJ; Valentijn AR; Fathers LM; Oostendorp J; van der Zee AG; Melief CJ; van der Burg SH; Daemen T; Nijman HW
Int J Cancer; 2009 Nov; 125(9):2104-13. PubMed ID: 19621448
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study.
Vermeij R; Leffers N; Hoogeboom BN; Hamming IL; Wolf R; Reyners AK; Molmans BH; Hollema H; Bart J; Drijfhout JW; Oostendorp J; van der Zee AG; Melief CJ; van der Burg SH; Daemen T; Nijman HW
Int J Cancer; 2012 Sep; 131(5):E670-80. PubMed ID: 22139992
[TBL] [Abstract][Full Text] [Related]
5. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.
van der Burg SH; Menon AG; Redeker A; Bonnet MC; Drijfhout JW; Tollenaar RA; van de Velde CJ; Moingeon P; Kuppen PJ; Offringa R; Melief CJ
Clin Cancer Res; 2002 May; 8(5):1019-27. PubMed ID: 12006514
[TBL] [Abstract][Full Text] [Related]
6. Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer.
Leffers N; Vermeij R; Hoogeboom BN; Schulze UR; Wolf R; Hamming IE; van der Zee AG; Melief KJ; van der Burg SH; Daemen T; Nijman HW
Int J Cancer; 2012 Jan; 130(1):105-12. PubMed ID: 21328579
[TBL] [Abstract][Full Text] [Related]
7. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678
[TBL] [Abstract][Full Text] [Related]
8. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
9. Magnitude and polarization of P53-specific T-helper immunity in connection to leukocyte infiltration of colorectal tumors.
van der Burg SH; Menon AG; Redeker A; Franken KL; Drijfhout JW; Tollenaar RA; Hartgrink HH; van de Velde CJ; Kuppen PJ; Melief CJ; Offringa R
Int J Cancer; 2003 Nov; 107(3):425-33. PubMed ID: 14506743
[TBL] [Abstract][Full Text] [Related]
10. Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2.
Svane IM; Pedersen AE; Nikolajsen K; Zocca MB
Vaccine; 2008 Aug; 26(36):4716-24. PubMed ID: 18616968
[TBL] [Abstract][Full Text] [Related]
11. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.
Snook AE; Baybutt TR; Xiang B; Abraham TS; Flickinger JC; Hyslop T; Zhan T; Kraft WK; Sato T; Waldman SA
J Immunother Cancer; 2019 Apr; 7(1):104. PubMed ID: 31010434
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
Matsushita N; Aruga A; Inoue Y; Kotera Y; Takeda K; Yamamoto M
Oncol Rep; 2013 Mar; 29(3):951-9. PubMed ID: 23314271
[TBL] [Abstract][Full Text] [Related]
13. Phase I dendritic cell p53 peptide vaccine for head and neck cancer.
Schuler PJ; Harasymczuk M; Visus C; Deleo A; Trivedi S; Lei Y; Argiris A; Gooding W; Butterfield LH; Whiteside TL; Ferris RL
Clin Cancer Res; 2014 May; 20(9):2433-44. PubMed ID: 24583792
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
[TBL] [Abstract][Full Text] [Related]
15. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells.
Babatz J; Röllig C; Löbel B; Folprecht G; Haack M; Günther H; Köhne CH; Ehninger G; Schmitz M; Bornhäuser M
Cancer Immunol Immunother; 2006 Mar; 55(3):268-76. PubMed ID: 16034561
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
Kakimi K; Isobe M; Uenaka A; Wada H; Sato E; Doki Y; Nakajima J; Seto Y; Yamatsuji T; Naomoto Y; Shiraishi K; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Oka M; Pan L; Hoffman EW; Old LJ; Nakayama E
Int J Cancer; 2011 Dec; 129(12):2836-46. PubMed ID: 21448901
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer.
Kibe S; Yutani S; Motoyama S; Nomura T; Tanaka N; Kawahara A; Yamaguchi T; Matsueda S; Komatsu N; Miura M; Hinai Y; Hattori S; Yamada A; Kage M; Itoh K; Akagi Y; Sasada T
Cancer Immunol Res; 2014 Dec; 2(12):1154-62. PubMed ID: 25351849
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma.
Uemura H; Fujimoto K; Tanaka M; Yoshikawa M; Hirao Y; Uejima S; Yoshikawa K; Itoh K
Clin Cancer Res; 2006 Mar; 12(6):1768-75. PubMed ID: 16551861
[TBL] [Abstract][Full Text] [Related]
20. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]